Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9030310 | 0.88 | NPC1 (0.38) | NPC1NCF1OPRM1HRH3CHRM2 | |
| SCHEMBL13162853 | 0.88 | KMT2A (0.36) | NPC1NCF1KMT2ACHRM2CHRM1 | |
| SCHEMBL18912346 | 0.88 | KMT2A (0.36) | NPC1NCF1KMT2ACHRM2CHRM1 | |
| SCHEMBL13561507 | 0.88 | KMT2A (0.36) | NPC1NCF1KMT2ACHRM2CHRM1 | |
| SCHEMBL27396399 | 0.88 | NPC1 (0.38) | NPC1NCF1OPRM1HRH3CHRM2 | |
| SCHEMBL26381329 | 0.84 | NPC1 (0.36) | NPC1NCF1OPRM1HRH3CHRM2 | |
| SCHEMBL21468985 | 0.83 | LIPC (0.41) | NPC1NCF1OPRM1KMT2ACHRM2 | |
| SCHEMBL12200376 | 0.81 | NPC1 (0.34) | NPC1OPRM1 | |
| SCHEMBL13652632 | 0.81 | — | — | |
| SCHEMBL17625276 | 0.81 | NPC1 (0.35) | NPC1OPRM1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11453667-B2 | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-09-27 | — | — | US | disclosed |
| US-20210371411-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| WO-2021129653-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | 上海济煜医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-20210147418-A1 | Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor | MEDSHINE DISCOVERY INC (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3390339-A1 | PRODUCTION OF TERT-BUTYL ESTERS OF ETHYLENICALLY UNSATURATED CARBOXYLIC ACIDS | BASF SE (DE) | 2018-10-24 | — | — | EP | disclosed |
| EP-3309148-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9944625-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | NPC1 1131/4885NCF1 544/4885OPRM1 3434/4885 |
| US-11453667-B2 | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor | KRAS, NRAS, MSH2 | NPC1 4576/4885NCF1 2427/4885OPRM1 4109/4885 |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | NPC1 3153/4885NCF1 2081/4885OPRM1 2248/4885 |
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | KRAS, NRAS, MSH2 | NPC1 4607/4885NCF1 1970/4885OPRM1 4140/4885 |
| US-20210147418-A1 | Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor | KRAS, NRAS, MSH2 | NPC1 4576/4885NCF1 2427/4885OPRM1 4109/4885 |
| US-20210371411-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | KRAS, NRAS, MSH2 | NPC1 4576/4885NCF1 2427/4885OPRM1 4109/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | NPC1 2687/4885NCF1 991/4885OPRM1 4284/4885 |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | HSPBP1, HSF1, HSPH1 | NPC1 2793/4885NCF1 1071/4885OPRM1 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.